Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Sector news Pharmaceuticals - NEC
07/20GLAXOSMITHKLINE : considers splitting up the group - FT
RE
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20GLAXOSMITHKLINE : considers splitting up the group
RE
07/20GLAXOSMITHKLINE : Mulls Separation of Consumer Division -- FT
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20Swiss, German drugmakers join U.S. price freeze
RE
07/20BAYER : to phase out Essure birth control device in U.S.
RE
07/20BAYER : Voluntarily Discontinues Sales of Essure in U.S.
DJ
07/20ASTRAZENECA : EU drug regulators step up work to prepare for 'no deal' Brexit
RE
07/20Battle lines drawn as EU court weighs fate of gene-edited crops
RE
07/20MERCK AND : to Cut Drug Prices Amid Pressure -- WSJ
DJ
07/20SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/19AMGEN : and Cedars-Sinai in Collaboration for 'Health-Care Quality'
DJ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK AND : Announces Plan to Lower Prices of Some Drugs
DJ
07/19JOHNSON & JOHNSON : Women who sued J&J declare victory after $4.69 billion talc ..
RE
07/19Barclays Poaches Senior Health-Care Banker From Deutsche Bank
DJ
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/19Finance Chiefs Say Too Much Data Is Making It Harder to Keep on Top of Risks
DJ
07/19Barclays appoints Campili as vice chairman for healthcare banking
RE
07/19NOVARTIS : Freezes Its Drug Prices -- WSJ
DJ
07/19SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
07/18NOVARTIS : FDA Expands Approval of Novartis Breast Cancer Drug
DJ
07/18ABBOTT LABORATORIES : on Track for All-Time High After 2Q Earnings -- Data Talk
DJ
07/18NOVARTIS : to Refrain From Rising U.S. Drug Prices -- 3rd Update
DJ
07/18NOVARTIS : to Refrain From Raising U.S. Drug Prices -- 2nd Update
DJ
07/18ABBOTT LABORATORIES : Sales Rise, Lifts Full-Year Outlook -- Earnings Review
DJ
07/18NOVARTIS : to Refrain From Raising U.S. Drug Prices -- Update
DJ
07/18Pfizer, Lilly See Positive Top-Line Results From Phase 3 Trial of Tanezumab
DJ
07/18ASTRAZENECA : Increases Drug Stockpile in Preparation for Hard Brexit
DJ
07/18ASTRAZENECA : to stockpile drugs as Brexit 'safety net'
RE
07/18NOVARTIS : Backs 2018 Outlook, Says Cohen Affair Is 'Closed' -- Update
DJ
07/18JOHNSON & JOHNSON : J&J's Pharma Business Fuels Sales Growth -- WSJ
DJ
07/18NOVARTIS : Backs 2018 Outlook After Sales Grow
DJ
07/17JOHNSON & JOHNSON : J&J beats quarterly expectations on drug sales surge, shares..
RE
07/17JOHNSON & JOHNSON : Pharma Business Fuels Sales Growth -- Update
DJ
07/17Johnson & Johnson on Track for Largest Intraday Percent Increase Since Jan 20..
DJ
07/17ABBVIE : Signs Humira Patent License with Mylan
DJ
07/17JOHNSON & JOHNSON : Pharmaceuticals Business Delivers, but Company Lowers Sales ..
DJ
07/17Investor 2Q Net Profit Rises 34%
DJ
07/17SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/16Startup Producing Cell-Grown Meat Raises New Funding
DJ
07/16J&J'S JANSSEN : Credence Trial of Invokana Being Stopped Early for Positive Effi..
DJ
07/16ASTRAZENECA : Swedish Business Appoints New CEO
DJ
07/16Indivior's shares soar 33 percent after U.S. court blocks sale of rival gener..
RE
07/16SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/13TEVA PHARMACEUTICAL INDUSTRIES : FDA Recalls Several Medicines That Contain Vals..
DJ
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 14 930 M
EBIT 2018 8 452 M
Net income 2018 4 841 M
Debt 2018 11 631 M
Yield 2018 -
P/E ratio 2018 13,33
P/E ratio 2019 10,50
EV / Sales 2018 4,92x
EV / Sales 2019 4,02x
Capitalization 61 857 M
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
CELGENE CORPORATION-18.46%61 857
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171
AMGEN9.54%126 889
ABBOTT LABORATORIES10.95%111 818
SANOFI0.71%105 544
GLAXOSMITHKLINE17.19%101 446
BAYER-10.06%100 917
ELI LILLY AND COMPANY4.75%97 070
NOVO NORDISK A/S-4.90%95 716
ASTRAZENECA9.14%92 447
BRISTOL-MYERS SQUIBB COMPANY-7.46%92 417
ALLERGAN PLC5.02%58 790
SHIRE12.37%52 878
JIANGSU HENGRUI MEDICINE CO LTD38.09%40 172
TAKEDA PHARMACEUTICAL CO LTD-27.26%33 746
ASTELLAS PHARMA INC24.72%32 108
EISAI CO., LTD71.62%29 654